Drug Approval | January 31, 2023
CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
